Irrimax

What Irrimax does

Irrimax Corporation is a privately held U.S. medical device company headquartered in Lawrenceville, Georgia, and a wholly owned subsidiary of Innovation Technologies, Inc., which holds the underlying patents. Founded in 2003, the company develops, manufactures, and commercializes the Irrisept Antimicrobial Wound Lavage system, a self-contained jet lavage containing 0.05% chlorhexidine gluconate (CHG) as a preservative in 99.95% sterile water, aseptically filled using Blow-Fill-Seal technology. The product portfolio includes 450mL and 150mL bottle configurations tailored to acute care, post-acute, and pre-hospital/field use, plus Irrisept Accessory Kit and Wound Solution Kit (launched August 2024) that integrate the solution with powered irrigation, pulse lavage, and negative pressure wound therapy devices. Supporting accessories include the Irriprobe applicator and Splatterguard splash reduction accessory.

The business model is a one-time unit-sale medical device model: Irrisept is sold through a combination of direct field sales representatives and an extensive U.S. distributor network (Amerisource Bergen, Cardinal Health, McKesson, Medline, Henry Schein, Owens & Minor, plus the VA), as well as international distribution partners in Canada, Mexico, and New Zealand, with regulatory clearance also secured in Brazil, Chile, Panama, and Saudi Arabia. Products are Rx-only (prescription restricted) and target acute care hospitals, surgical specialties (cardiac, orthopedic, urologic, vascular, general), pre-hospital/emergency medical services, and post-acute outpatient settings; the company claims adoption across more than 4,500 U.S. hospitals and over 2.5 million lifetime uses. Go-to-market is supported by a Medical Advisory Board of 10 physicians chaired by Dr. Antonia Chen of Harvard Medical School and a Medical Affairs Team providing credentialed continuing education.

In August 2024, global healthcare private equity firm ARCHIMED acquired Irrimax (including Innovation Technologies) for an undisclosed sum through its MED Platform II fund, explicitly to expand product range, markets, and global reach. ARCHIMED partners Carlos Alonso and Kent Davies (former President and COO of PDI) joined Irrimax's board as part of the transaction, signaling a growth-capital mandate rather than a turnaround.

Name

Irrimax

Legal name

Irrimax Corporation

Website

https://irrisept.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

11–50 employees

Short description

Irrimax is a U.S. medical device company that develops and sells Irrisept, a self-contained antimicrobial wound lavage using 0.05% chlorhexidine gluconate as a preservative, serving over 4,500 U.S. hospitals and international markets through distributors and direct sales. In August 2024 it was acquired by healthcare private equity firm ARCHIMED.

Ownership category

akta.pro rank

Product category

Antimicrobial Wound Irrigation Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Antimicrobial Wound Care (Silver/Iodine/PHMB Dressings, Wound Irrigation) (HLAHALAC)

Keywords

• Antimicrobial wound irrigation
• Wound lavage devices
• Chlorhexidine gluconate solutions
• Pre-surgical wound cleansing
• Hospital infection prevention

Headquarters

HQ city

Atlanta

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Irrisept Antimicrobial Wound Lavage Device Sales: Irrimax generates revenue through the sale of its Irrisept Antimicrobial Wound Lavage medical devices. Products are sold through medical supply distributors and direct sales representatives. Revenue is one-time per unit transaction as a physical medical device product.

Go-to-market motion2 records

Distribution channels17 records

Marketing channels6 records

Core offering

Irrimax manufactures and sells the Irrisept Antimicrobial Wound Lavage, a self-contained jet lavage device containing 0.05% chlorhexidine gluconate (CHG) as a preservative in 99.95% Sterile Water for Irrigation, USP. The product mechanically cleanses wounds by removing debris, dirt, and microorganisms under low pressure, and is offered in multiple sizes (450 mL, 150 mL) and configurations for acute care, post-acute, and pre-hospital/field settings, along with accessory kits for powered irrigation.

Product overview

Irrimax offers a portfolio of medical devices centered on its flagship Irrisept Antimicrobial Wound Lavage system. The core product is a self-contained jet lavage containing 0.05% chlorhexidine gluconate (CHG) as a preservative for wound irrigation. The portfolio includes multiple configurations: 450mL and 150mL sterile-packaged bottles for acute care, 150mL post-acute wound care with Splatterguard, and 150mL Tear & Go pouch for pre-hospital/field use. Supporting products include the Accessory Kit (spikeable connection for powered irrigation devices) and Wound Solution Kit (instillable configuration), both launched in August 2024 as Phase II of the innovation pipeline. Accessories include the Irriprobe applicator and Splatterguard. The company was acquired by healthcare private equity firm ARCHIMED in August 2024.

Differentiator

Problem solved

Functional benefit

Brands

• Irrisept: Antimicrobial Wound Lavage product line containing 0.05% chlorhexidine gluconate (CHG) as a preservative for wound irrigation
• Irriprobe
• Splatterguard

Products and services

• Irrisept Antimicrobial Wound Lavage (450 mL, Sterile Packaged) Self-contained 450 mL jet lavage containing 0.05% chlorhexidine gluconate (CHG) as a preservative in 99.95% Sterile Water for Irrigation, USP. Delivers low-pressure irrigation (1–15 psi) for mechanical cleansing and removal of debris, dirt, and foreign materials including microorganisms from wounds, and is for use in hospitals and other acute care settings under physician order (Rx only).
• Irrisept Antimicrobial Wound Lavage (150 mL, Sterile Packaged) Self-contained 150 mL jet lavage containing 0.05% CHG in 99.95% Sterile Water for Irrigation, USP, with new packaging and bottle design. Provides low-pressure wound irrigation for acute care settings in a smaller unit-of-use configuration.
• Irrisept Antimicrobial Wound Lavage (150 mL, Post-Acute Wound Care) Self-contained 150 mL jet lavage with attachable Splatterguard in easy-to-store shelf carton, designed for wound care and cleansing in post-acute settings such as outpatient clinics and skilled nursing facilities.
• Irrisept Antimicrobial Wound Lavage (150 mL, Tear & Go Pouch) Self-contained 150 mL jet lavage with detachable Splatterguard in a Tear & Go Pouch for pre-hospital and field-care use, designed for easy transport and immediate use as a frontline defense to cleanse and remove debris from wounds before hospital treatment.
• Irrisept Accessory Kit (ISEPT-AK-USA) Spikeable connection accessory kit for use with the 450 mL Irrisept bottle, including a vented spike, spikable cap, and two bottle hangers. Enables connection to powered irrigation devices for use in acute hospital settings.
• Irrisept Wound Solution Kit (ISEPT-WS-USA) Instillable configuration pairing a 450 mL Irrisept Antimicrobial Wound Lavage bottle with a spikable cap and two bottle hangers, intended for use with powered irrigation systems such as suction irrigation, pulse lavage, and negative pressure wound therapy in hospital settings.

Quantifiable outcome

• Trusted by more than 4,500 U.S. hospitals
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• Surgi-One Medical TechnologiescoreChannel Partner/ Reseller/ Distributor · 1 October 2022Surgi-One Medical Technologies is Irrimax's Canadian distribution partner. President Bill MacDonald believes providing clients access to products like Irrisept helps reduce possibility of infection and allows them to focus on other vital areas of care.
• Sanabria Corporativo Medico S.A.coreChannel Partner/ Reseller/ Distributor · 1 October 2022Sanabria Corporativo Medico S.A. is Irrimax's Mexican distribution partner. The company serves the medical community by supplying operating rooms and emergency services with patient monitoring and other important medical devices. Dr. Salvador Sanabria, Director General, stated that adding Irrisept gives clinicians another tool to help fight infection.
• DBM Medical GroupcoreChannel Partner/ Reseller/ Distributor · 1 October 2022DBM Medical Group is Irrimax's inaugural New Zealand distributor. DMB currently supplies medical products to every hospital in New Zealand. Director Courtney MacKay believes Irrisept can become Standard of Care in New Zealand.
• Dr. Antonia Chen (Harvard Medical School)coreStrategic or Co-development Partner · 1 July 2022Dr. Antonia Chen, Associate Professor at Harvard Medical School, chairs the Irrimax Medical Advisory Board. She stated that Irrisept is a market leader in irrigation and she is excited to help lead the team to advance Irrimax's mission of reducing infections and improving patient outcomes.
• Irrimax Medical Advisory Board MemberscoreStrategic or Co-development Partner · 1 July 2022Ten physicians across multiple specialties including Dr. Garrick Cason (UTCOM/Academic Spine Surgeon), Dr. Philip Corvo (St. Mary's Hospital), Dr. Edward Karpman (El Camino Hospital), Dr. Laurence Levine (Rush University Medical Center), Dr. Calvin J. Rushing (Dallas Orthopedic and Shoulder Institute), Dr. Mohsin Soliman (Menorah Medical Center), Dr. Ian Valerio (Massachusetts General Hospital), Dr. Hans P. Van Lancker (St. Elizabeth's Medical Center), Dr. Ian Weber (Cornerstone Orthopaedics), and Dr. Paul Naylor (Chief Medical Officer). Members are national leaders with prominent positions in medical societies, published authors and researchers.
• Project MedishareminorOthers · 1 August 2021Irrimax partnered with Project Medishare via Infection Reduction Partners (IRP) to donate Irrisept antimicrobial wound lavage products for Haiti earthquake relief efforts. Project Medishare provides vital medical work during times of extraordinary need.
• Infection Reduction Partners (IRP)minorStrategic or Co-development Partner · 1 August 2021IRP facilitated the partnership between Irrimax and Project Medishare for Haiti earthquake relief efforts.
• Innovation Technologies, Inc.coreOthersInnovation Technologies, Inc. is the parent company of Irrimax Corporation. Innovation Technologies holds the rights to US and worldwide patents that provide broad protection for the use of low-concentration chlorhexidine gluconate (less than 1%) technology. Irrisept, Irriprobe, and Splatterguard are registered trademarks of Innovation Technologies, Inc.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• 3M Health Care: 3M's Health Care division includes surgical antiseptics, wound cleansers, and skin prep products sold to hospitals through overlapping distribution channels, competing with Irrisept across CHG-based and adjunct antiseptic categories.
• Stryker: Stryker's Medical/Surgical division includes pulse lavage and powered irrigation systems used for orthopedic and surgical wound irrigation in the same operating-room settings where Irrisept is used, making it a partial competitor with a much broader device portfolio.
• Becton Dickinson (BD): BD is a large diversified medical device and life sciences company with a surgical and infection prevention portfolio that includes surgical irrigation products, skin prep antiseptics, and wound care solutions, overlapping with Irrisept's antimicrobial wound lavage category across hospital customers.

Direct peers

• ConvaTec: ConvaTec is a global wound care and ostomy specialist with antimicrobial wound cleansers and irrigation solutions sold to hospitals and post-acute care settings, making it a directly comparable peer in CHG and antiseptic wound lavage.
• Mölnlycke Health Care: Mölnlycke is a wound care and surgical solutions specialist that markets Hibiclens (chlorhexidine-based antiseptic) and a portfolio of wound irrigation and management products targeting the same surgical and infection-prevention use cases as Irrisept.
• Baxter International: Baxter manufactures sterile irrigation solutions (saline, water) and pharmacy compounding products used in wound care and surgical settings, directly competing with Irrisept's sterile water-based antimicrobial wound lavage category.
• Smith+Nephew: Smith+Nephew is a global medical device company with a dedicated Advanced Wound Management franchise that competes in antimicrobial wound cleansers, irrigation, and dressings sold to the same acute and post-acute hospital customers served by Irrisept.
• Coloplast: Coloplast operates a dedicated Wound & Skin Care business offering antimicrobial cleansers, wound irrigation, and dressings for hospital and home care, closely overlapping with Irrisept's antimicrobial wound care positioning.

Emerging players

• Microcyn Technology (Oculus Innovative Sciences): Microcyn / Oculus markets hypochlorous acid-based wound cleansers and irrigation products as an alternative preservative chemistry to Irrisept's CHG-based lavage, targeting the same wound care and infection reduction use cases.
• Anasept (Applied BioSciences): Anasept offers a silver-based antimicrobial wound cleanser and skin cleanser competing directly with Irrisept in CHG-adjacent wound irrigation categories sold to hospitals, wound clinics, and post-acute settings.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Irrimax